Appendix Table 17KQ3 Atrial fibrillation—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Study, yearStudy DesignPopulationOutcome/DefinitionGroupEvents, n/NEvents, “X”R (95% CI)
MARCATOR, 199553RCTUndergoing elective coronary angioplastyNRCilazapril 20mg/d
Placebo
NRNR
APRES, 200054RCTUnderwent elective CABG (82%; 5–7 days prior to randomization) or PTCA (18%; 1–2 days prior to randomization) for anginaNRRamipril 10mg/d
Placebo
NRNR
Kondo et al, 200155RCTReceived elective balloon angioplasty followed by coronary stentingNRQuinapril 20mg/d
Control
NRNR
PARIS, 200156RCTUnderwent successful elective PCI with stent implantationNRQuinapril 40mg/d
Placebo
NRNR
QUIET, 200157RCTUnderwent successful elective coronary angioplasty of atherectomy within 12–72 hoursNRQuinapril 20mg/d
Placebo
NRNR
AACHEN, 200658RCTUndergoing elective coronary stent implantation (treatment started 7–14 days prior to intervention)NRCandesartan 32mg/d
Placebo
NRNR
IMAGINE, 200859RCTUnderwent CABG (7–10 days prior)New-onset atrial fibrillation (after randomization)Quinapril 40 mg/d
Placebo
114/1280
101/1273
% risk difference 1 (−1.2 to 3.1)

From: Appendix C, Additional Evidence Tables and Analyses

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.